Tirkkonen, T <br/><br/>
Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide.  [electronic resource] 

 -  Journal of internal medicine  Oct 2010 
 - 359-66 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2796 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2796.2010.02257.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Aryl Hydrocarbon Hydroxylases--antagonists & inhibitors<br/>Cytochrome P-450 CYP2C9<br/>Diabetes Mellitus, Type 2--drug therapy<br/>Drug Interactions<br/>Female<br/>Glipizide--therapeutic use<br/>Glyburide--therapeutic use<br/>Hospitalization<br/>Humans<br/>Hypoglycemic Agents--therapeutic use<br/>Male<br/>Middle Aged<br/>Sulfonylurea Compounds--therapeutic use<br/>Young Adult